CROSSJECT (EPA:ALCJ) | Finanzwire

Basculer en Français

10603	Companies
225009	Keywords
153732	Articles
119071	Press releases

Home
Companies
CROSSJECT

PRESS RELEASE

published on 06/24/2025 at 19:00, 11 months 26 days ago

CROSSJECT announces a successful capital increase of €5.7 million following full exercise of the extension clause
CROSSJECT successfully completes a capital increase of €5.7 million through preferential subscription rights, benefiting from new investor support and Gemmes Venture, to advance ZEPIZURE® development

Capital Increase Crossject ZEPIZURE® Gemmes Venture Vatel Capital
BRIEF

published on 06/11/2025 at 07:35, 1 year ago

CROSSJECT advances in the development of ZEPIZURE® Junior for children

Epilepsy Pediatrics Crossject Auto-injector ZEPIZURE Junior
PRESS RELEASE

published on 06/11/2025 at 07:30, 1 year ago

CROSSJECT advances on the development of ZEPIZURE® Junior, its solution for epilepsy crises in children
CROSSJECT advances development of ZEPIZURE® Junior for epilepsy crises in children, completing clinical studies for effective calibration and injection depth validation

Epilepsy Clinical Studies Crossject ZEPIZURE® Junior Pediatric Population
BRIEF

published on 06/06/2025 at 17:50, 1 year ago

Publication of Crossject voting rights and shares

Share Capital Voting Rights Actions AMF Crossject
BRIEF

published on 06/04/2025 at 20:26, 1 year ago

CROSSJECT launches a capital increase of nearly 5 million euros

Investment Pharmaceutical Capital Increase Preferential Subscription Right ZEPIZURE®
PRESS RELEASE

published on 06/04/2025 at 20:21, 1 year ago

Launch of a capital increase with preferential subscription rights for nearly 5 million euros
CROSSJECT announces capital increase with preferential subscription rights totaling nearly 5 million euros. Existing shareholders and Vatel Capital commit to subscribe 76.4% of the amount. Subscription price set at 1.40 euros. Subscription period from June 12 to June 20, 2025

Capital Increase Subscription Period Preferential Subscription Rights Crossject Vatel Capital
BRIEF

published on 06/03/2025 at 07:35, 1 year ago

Maxim Group Recommends CROSSJECT with €4.00 Target Price

Buy Recommendation Crossject ZEPIZURE® Needle-free Auto-injector Maxim Group
PRESS RELEASE

published on 06/03/2025 at 07:30, 1 year ago

Maxim Group initiates the coverage of the CROSSJECT share with a BUY recommendation and a target price of €4.00
Maxim Group initiates coverage of CROSSJECT with BUY recommendation and €4.00 target price. CROSSJECT, a specialty pharma company, looks forward to positive developments with FDA and pipeline

FDA Buy Recommendation Specialty Pharma Crossject Maxim Group
BRIEF

published on 05/27/2025 at 07:35, 1 year ago

CROSSJECT optimizes its production with the ZENEO® Nest

CDMO Funding Production Crossject ZENEO® Nest
BRIEF

published on 05/20/2025 at 07:35, 1 year 1 month ago

CROSSJECT Plans €5 Million Capital Increase to Boost EUA Approval Activities

Capital Increase Crossject ZEPIZURE® Gemmes Venture EUA Approval

Accesswire

Published on 06/20/2026 at 01:00, 19 hours 4 minutes ago

Onco-Innovations Announces Non-Brokered LIFE Offering
Published on 06/20/2026 at 00:00, 20 hours 4 minutes ago

Onco-Innovations Reports Completion of 300g Active Pharmaceutical Ingredient for ONC010 Scale-Up Supporting IND-Enabling Development
Published on 06/19/2026 at 04:30, 1 day 15 hours ago

Uraniumx Discovery Corp. Announces Acquisition of Common Shares of Gold'n Futures Mineral Corp
Published on 06/19/2026 at 01:20, 1 day 18 hours ago

American Hotel Income Properties REIT LP Reports Voting Results of Annual and Special Meeting
Published on 06/19/2026 at 01:07, 1 day 18 hours ago

Usha Resources Announces Share Issuance in Payment of Debenture Interest, Adopts Semi-Annual Reporting

View all ACCESSWIRE

EQS Group

Published on 06/20/2026 at 06:00, 14 hours 3 minutes ago

Successful debut of International Symposium on Emergency Response and Aeromedical Services in Hong Kong
Published on 06/19/2026 at 20:17, 23 hours 46 minutes ago

2CRSi SA: 2CRSi Responds Point-by-Point to the Grizzly Research Report and Reaffirms the Reality of Its Business Operations
Published on 06/19/2026 at 19:01, 1 day 1 hour ago

Fuller, Smith & Turner PLC: Publication of the Annual Report and Accounts for the 52 weeks ending 28 March 2026 and Notice of 2026 Annual General Meeting
Published on 06/19/2026 at 18:29, 1 day 1 hour ago

Designated Person Notification
Published on 06/19/2026 at 18:00, 1 day 2 hours ago

Successful issue of a CHF 100 million green bond

Les Echos

Published on 06/19/2026 at 19:33, 1 day ago

Disclosure of transactions in own shares from June 15 to June 19, 2026
Published on 06/19/2026 at 19:23, 1 day ago

Imerys-06-2026-information-share-capital-and-voting-rights-as-of-31-May-2026
Published on 06/18/2026 at 18:00, 2 days 2 hours ago

Outstanding shares and voting rights statement at 31 May 2026
Published on 06/18/2026 at 17:45, 2 days 2 hours ago

EURAZEO INVESTS IN LAURALU, A PAN-EUROPEAN PROVIDER OF DEPLOYABLE INDUSTRIAL INFRASTRUCTURE
Published on 06/18/2026 at 17:38, 2 days 2 hours ago

Statement of transactions in own shares from June 8, 2026 to June 12, 2026

View all LES ECHOS COMFI WIRE